Sign In
Buy EXEL
$56.70
+0.700 (+1.25%)
At Close: Aug 05, 2026
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
10:45am, Monday, 15'th Dec 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
California Public Employees Retirement System Sells 762,866 Shares of Exelixis, Inc. $EXEL
04:30am, Friday, 12'th Dec 2025
California Public Employees Retirement System decreased its position in Exelixis, Inc. (NASDAQ: EXEL) by 59.2% during the undefined quarter, according to its most recent filing with the SEC. The insti
Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day Transcript
06:12am, Thursday, 11'th Dec 2025
Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day Transcript
Cresset Asset Management LLC Sells 21,295 Shares of Exelixis, Inc. $EXEL
04:07am, Thursday, 11'th Dec 2025
Cresset Asset Management LLC cut its position in shares of Exelixis, Inc. (NASDAQ: EXEL) by 44.0% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange
Why Is Exelixis (EXEL) Up 9% Since Last Earnings Report?
12:37pm, Thursday, 04'th Dec 2025
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
04:05pm, Wednesday, 03'rd Dec 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast its virtual event, Exelixis 2025 R&D Day: Building Next-generation Oncology Franchises, on Wednesda
Arrowstreet Capital Limited Partnership Grows Holdings in Exelixis, Inc. $EXEL
03:20am, Wednesday, 03'rd Dec 2025
Arrowstreet Capital Limited Partnership lifted its position in shares of Exelixis, Inc. (NASDAQ: EXEL) by 42.9% during the second quarter, according to the company in its most recent filing with the S
2 Under-the-Radar Stocks to Buy Heading Into 2026
08:06pm, Monday, 01'st Dec 2025
Axsome Therapeutics boasts a deep late-stage pipeline with billions in potential revenue opportunity. Exelixis' core franchise remains strong while it develops promising new medicines.
Capital Fund Management S.A. Acquires 17,673 Shares of Exelixis, Inc. $EXEL
04:14am, Saturday, 29'th Nov 2025
Capital Fund Management S.A. increased its holdings in shares of Exelixis, Inc. (NASDAQ: EXEL) by 6.6% in the second quarter, according to the company in its most recent Form 13F filing with the Secur
Here's Why Exelixis (EXEL) is a Strong Growth Stock
10:46am, Friday, 28'th Nov 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Exelixis (EXEL) International Revenue Trends Deserve Your Attention
10:16am, Monday, 17'th Nov 2025
Evaluate Exelixis' (EXEL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
10:51am, Thursday, 13'th Nov 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
10:46am, Tuesday, 11'th Nov 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript
01:41pm, Monday, 10'th Nov 2025
Exelixis, Inc. ( EXEL ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 10:30 AM EST Company Participants Michael Morrissey - CEO, President & Director Conference C
Exelixis: The STELLAR Win Is A Mixed Bag, But Things Look Positive Still
09:39pm, Thursday, 06'th Nov 2025
Exelixis is positioned for growth with positive phase 3 data for zanzalintinib in metastatic colorectal cancer, following cabozantinib's success. STELLAR-303 results show modest survival benefit but i
